M&T Bank Corp Sells 39,705 Shares of Takeda Pharmaceutical Co. $TAK

M&T Bank Corp cut its stake in Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 58.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,810 shares of the company’s stock after selling 39,705 shares during the period. M&T Bank Corp’s holdings in Takeda Pharmaceutical were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of TAK. Private Trust Co. NA increased its holdings in shares of Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. True Wealth Design LLC lifted its holdings in Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after buying an additional 2,512 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares in the last quarter. Advisory Services Network LLC bought a new position in Takeda Pharmaceutical in the 3rd quarter valued at $74,000. Finally, Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 24.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock valued at $102,000 after buying an additional 1,378 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

TAK opened at $16.63 on Friday. The company has a fifty day moving average price of $17.94 and a two-hundred day moving average price of $16.25. The firm has a market capitalization of $52.91 billion, a PE ratio of 69.27 and a beta of -0.06. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The company had revenue of $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Read Our Latest Stock Report on Takeda Pharmaceutical

Takeda Pharmaceutical Company Profile

(Free Report)

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

Featured Stories

• Five stocks we like better than Takeda Pharmaceutical

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).